Collectively, this evidence indicates that the blockade of NKG2A can also stimulate the CD8+ T cells-dependent anti-tumor immunity [131], and therefore, it can be considered a promising immunotherapy approach to boost the effector functions of both NK cells and CD8+ T cells against the tumor (Fig. 2). Here, KLRC1 is linked to neoplasm.